<DOC>
	<DOCNO>NCT01564251</DOCNO>
	<brief_summary>This open-label , multicenter , Phase I , dose-escalation study evaluate safety , tolerability , pharmacokinetics ( PK ) GDC-0575 administer alone combination gemcitabine participant refractory solid tumor lymphoma . In Stage 1 , cohort participant receive multiple ascend oral dos GDC-0575 alone combination intravenous gemcitabine . In Stage 2 , participant receive GDC-0575 orally combination intravenous gemcitabine maximum tolerate dose determined Stage 1 . Anticipated time study treatment disease progression unacceptable toxicity occur , approximately 5 year .</brief_summary>
	<brief_title>A Study GDC-0575 Alone Combination With Gemcitabine Participants With Refractory Solid Tumors Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>Eastern Cooperative Oncology Group ( ECOG ) performance status 01 Histologically cytologically document , locally advanced metastatic solid tumor lymphoma standard therapy either exist proven ineffective intolerable Life expectancy great equal ( &gt; = ) 12 week , opinion investigator Adequate hematologic , liver , renal function For Stage 2 : Participants human epidermal growth factor receptor 2 ( HER2 ) negative , estrogenreceptor ( ER ) negative , progesteronereceptor ( PR ) negative breast cancer For Stage 2 : Participants nonmucinous , platinumresistant ovarian cancer document radiographic progression relapse accord RECIST within 6 month receive platinumbased chemotherapy For Stage 2 : Participants histologically cytologically confirm diagnosis squamous nonsmall cell lung cancer ( NSCLC ) ; mixed histology predominantly squamous acceptable History prior significant toxicity class agent GDC0575 gemcitabine require discontinuation treatment All acute toxicity relate prior therapy must resolve prior study entry , except alopecia mild neuropathy Current severe , uncontrolled systemic disease ( include limit clinically significant cardiovascular , pulmonary , renal disease ongoing active infection ) exclude cancer study History significant cardiac dysfunction History malabsorption condition would interfere enteral absorption Known human immunodeficiency virus ( HIV ) infection Pregnancy , lactation breastfeed Known brain metastasis untreated , symptomatic , require therapy control symptom Current use alphaadrenergic receptor blocker For Combination Arm : Any contraindication gemcitabine therapy More two regimen cytotoxic chemotherapy treatment locally advance metastatic cancer History receive highdose chemotherapy require bone marrow stem cell support Irradiation 25 % bone marrowbearing area</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>